Lubiprostone: A novel chloride channel activator for the treatment of constipation

Formulary

Volumn 41, Issue 3, 2006, Pages 118-129

  Orr, Katherine Kelly ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITIZA; BISACODYL; CHLORIDE CHANNEL; DOCUSATE SODIUM; GLYCEROL; ISPAGULA; LUBIPROSTONE; MACROGOL; MAGNESIUM CITRATE; MAGNESIUM OXIDE; METHYLCELLULOSE; MINERAL OIL; PLACEBO; PROKINETIC AGENT; SENNA EXTRACT; SEROTONIN 4 ANTAGONIST; SODIUM DIHYDROGEN PHOSPHATE; TEGASEROD;

ABDOMINAL CRAMP; ASPIRATION PNEUMONIA; CHRONIC DISEASE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIURESIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FLATULENCE; GASTROINTESTINAL OBSTRUCTION; HEADACHE; HUMAN; IDIOPATHIC DISEASE; ILEUS; IRRITABLE COLON; NAUSEA; NEPHROTOXICITY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRURITUS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 33645574326     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):II43-II477. Available at: http://www.romecriteria. org/documents/GUTII/ibs997.pdf. Accessed March 1, 2006.
2. Everhart, J. E. (Ed.). (1994). Digestive diseases in the United States: Epidemiology and impact. (NIH Publication No. 94-1447). U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: U.S. Government Printing Office.
3. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci. 1989;34:606-611.
4. Velio P, Bassotti G. Chronic idiopathic constipation: Pathophysiology and treatment. J Clin Gastroenterol 1996;22:190-196.
5. Talley NJ, Jones M, Nutys G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol. 2003;98:110-111.
6. OTC sales by category. Consumer Healthcare Products Association. Available at: http://www.chpa-info.org/web/press_room/statistics/otc_sales.aspx. Accessed March 1, 2006.
7. Curry CE, Butler DM. Constipation. In: Berardi RR, ed. Handbook of Non-Prescription Drugs: An Interactive Approach to Self Care. 14th ed. Washington DC: American Pharmacists Association; 2004:367-403.
8. Zelnorm [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2004.
9. Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association Medical Position Statement: Guidelines on Constipation. Gastroenterology. 2000;119:1761-1778.
10. Sucampo Pharmaceuticals Inc. Sucampo obtains FDA approval for Amitiza capsules as treatment of chronic idiopathic constipation in adults. Media Release: January 31, 2006. Available at: http://www.sucampo.com/article_62. shtml, Accessed March 1, 2006.
11. Sucampo Pharmaceuticals Inc. Phase III clinical program evaluates lubiprostone. Media release, May 16,2005. Available at: http://www.sucampo. com/article_58.shtml. Accessed March 1, 2006.
12. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287: C1173-C1183.
13. Ueno R, Osama H, Habe T, Engelke K, Patchen M. Oral SP-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels [abstract]. Gastroenterology. 2004;126(suppl 2):A-100.
14. Amitiza [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc; 2006.
15. Johanson JF, Gargano MA, Patchen ML, Ueno R. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation [abstract]. Gastroenterology. 2002;122(suppl 1):A-315.
16. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation [abstract]. Gastroenterology. 2003;124(suppl 1):A-48.
17. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III study of lubiprostone, a chloride channel-2 (CIC-2) activator for treatment of constipation: safety and primary efficacy, [abstract]. Am J Gastroenterol. 2005;100(suppl 7):S328.
18. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation [abstract]. Gastroenterology. 2004;126(suppl 2):S100.
19. Johanson JF, Gargano MA, Patchen ML, Ueno R. Multi-center open-label study of lubiprostone for the treatment of chronic constipation, [abstract]. Am J Gastroenterol. 2005;100 (suppl 7):S331.
20. Data on file. Lubiprostone. Clinical study report (RTU/0211SC02S3). Bethesda, Md: Sucampo Pharmaceuticals, Inc. 2006.
21. Sucampo Pharmaceuticals Inc. Sucampo completes treatment in a phase II safety and efficacy IBS study with its chloride channel activator SP-0211. Media release, May 14, 2004. Available at: http://www.sucampo.com/article_42.shtml. Accessed March 1, 2006.